Matching articles for "iron"

Daprodustat (Jesduvroq) for Anemia of Chronic Kidney Disease

   
The Medical Letter on Drugs and Therapeutics • February 19, 2024;  (Issue 1696)
The FDA has approved daprodustat (Jesduvroq – GSK), a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for oral treatment of anemia due to chronic kidney disease (CKD) in adults who...
The FDA has approved daprodustat (Jesduvroq – GSK), a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for oral treatment of anemia due to chronic kidney disease (CKD) in adults who have been on dialysis for at least 4 months. It is the first HIF-PHI and the first oral drug to be approved in the US for this indication.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):25-7 | Show Full IntroductionHide Full Introduction

IV Ferric Carboxymaltose (Injectafer) for Iron Deficiency in Heart Failure

   
The Medical Letter on Drugs and Therapeutics • February 5, 2024;  (Issue 1695)
Ferric carboxymaltose (Injectafer – American Regent) is now FDA-approved for IV treatment of iron deficiency in adults with New York Heart Association (NYHA) class II/III heart failure to improve...
Ferric carboxymaltose (Injectafer – American Regent) is now FDA-approved for IV treatment of iron deficiency in adults with New York Heart Association (NYHA) class II/III heart failure to improve exercise capacity. Iron deficiency is present in approximately 30% of patients with heart failure; it has been associated with reduced quality of life and increased hospitalization and mortality. Injectafer is the first IV iron preparation to be approved for this indication. It was previously approved for treatment of iron deficiency anemia in children and adults.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):22-4 | Show Full IntroductionHide Full Introduction

Triferic for Iron Replacement

   
The Medical Letter on Drugs and Therapeutics • March 27, 2017;  (Issue 1517)
The FDA has approved ferric pyrophosphate citrate solution (Triferic – Rockwell Medical) to maintain hemoglobin concentrations in adults with hemodialysis-dependent chronic kidney disease. Triferic is the...
The FDA has approved ferric pyrophosphate citrate solution (Triferic – Rockwell Medical) to maintain hemoglobin concentrations in adults with hemodialysis-dependent chronic kidney disease. Triferic is the first iron replacement product that is added into the hemodialysis solution at each dialysis procedure.
Med Lett Drugs Ther. 2017 Mar 27;59(1517):55-6 | Show Full IntroductionHide Full Introduction

Drugs for Hypothyroidism

   
The Medical Letter on Drugs and Therapeutics • October 26, 2015;  (Issue 1480)
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy, or radioactive iodine therapy. Treatment of hypothyroidism with replacement doses of thyroid hormone is...
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy, or radioactive iodine therapy. Treatment of hypothyroidism with replacement doses of thyroid hormone is usually lifelong. Levothyroxine is the drug of choice.
Med Lett Drugs Ther. 2015 Oct 26;57(1480):147-50 | Show Full IntroductionHide Full Introduction

Ferric Carboxymaltose (Injectafer) for Iron Deficiency Anemia

   
The Medical Letter on Drugs and Therapeutics • December 9, 2013;  (Issue 1431)
The FDA has approved ferric carboxymaltose (Injectafer – American Regent), a 2-dose intravenous iron replacement product, for treatment of iron deficiency anemia (IDA) in adults who cannot tolerate...
The FDA has approved ferric carboxymaltose (Injectafer – American Regent), a 2-dose intravenous iron replacement product, for treatment of iron deficiency anemia (IDA) in adults who cannot tolerate or have had an unsatisfactory response to oral iron and in those who have non-dialysis-dependent chronic kidney disease (CKD). It is the sixth IV iron product approved in the US.
Med Lett Drugs Ther. 2013 Dec 9;55(1431):99-100 | Show Full IntroductionHide Full Introduction

Correction: Ferumoxytol (Feraheme)

   
The Medical Letter on Drugs and Therapeutics • April 19, 2010;  (Issue 1336)
In the Medical Letter article on Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation (2010; 52:23), the last sentence of the Dosage, Administration and Cost paragraph should have listed the cost of 1...
In the Medical Letter article on Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation (2010; 52:23), the last sentence of the Dosage, Administration and Cost paragraph should have listed the cost of 1 gram of sodium ferric gluconate (Ferrlecit) as about $600.
Med Lett Drugs Ther. 2010 Apr 19;52(1336):32 | Show Full IntroductionHide Full Introduction

Ferumoxytol (Feraheme) - A New Parenteral Iron Formulation

   
The Medical Letter on Drugs and Therapeutics • March 22, 2010;  (Issue 1334)
Ferumoxytol (Fer yoo mox’ i tole; Feraheme – AMAG), an intravenous (IV) iron replacement product, has been approved by the FDA for treatment of iron deficiency anemia in adults with chronic kidney disease....
Ferumoxytol (Fer yoo mox’ i tole; Feraheme – AMAG), an intravenous (IV) iron replacement product, has been approved by the FDA for treatment of iron deficiency anemia in adults with chronic kidney disease. Iron deficiency anemia is common in chronic kidney disease and may be associated with decreased absorption from the gastrointestinal tract, limiting the usefulness of oral iron replacement. IV iron replacement can lower the dose requirement for erythropoiesis-stimulating drugs, particularly in patients on dialysis
Med Lett Drugs Ther. 2010 Mar 22;52(1334):23-13 | Show Full IntroductionHide Full Introduction

Drugs for Thyroid Disorders

   
The Medical Letter on Drugs and Therapeutics • August 1, 2009;  (Issue 84)
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for...
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Treat Guidel Med Lett. 2009 Aug;7(84):57-64 | Show Full IntroductionHide Full Introduction

Ropinirole for Restless Legs Syndrome

   
The Medical Letter on Drugs and Therapeutics • August 1, 2005;  (Issue 1214)
Ropinirole (Requip - GlaxoSmithKline), a dopamine agonist already available for treatment of Parkinson's disease, is now the first drug approved by the FDA for treatment of moderate to severe restless legs...
Ropinirole (Requip - GlaxoSmithKline), a dopamine agonist already available for treatment of Parkinson's disease, is now the first drug approved by the FDA for treatment of moderate to severe restless legs syndrome (RLS).
Med Lett Drugs Ther. 2005 Aug 1;47(1214):62-4 | Show Full IntroductionHide Full Introduction

Generic drugs

   
The Medical Letter on Drugs and Therapeutics • October 14, 2002;  (Issue 1141)
When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent to the...
When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent to the brand-name product?
Med Lett Drugs Ther. 2002 Oct 14;44(1141):89-90 | Show Full IntroductionHide Full Introduction

Cefdinir--A New Oral Cephalosporin

   
The Medical Letter on Drugs and Therapeutics • August 28, 1998;  (Issue 1034)
Cefdinir (Omnicef - Parke-Davis), a third-generation oral cephalosporin, has been approved by the FDA for treatment of acute sinusitis, otitis media, acute exacerbations of chronic bronchitis, pharyngitis,...
Cefdinir (Omnicef - Parke-Davis), a third-generation oral cephalosporin, has been approved by the FDA for treatment of acute sinusitis, otitis media, acute exacerbations of chronic bronchitis, pharyngitis, community-acquired pneumonia and skin infections. Other drugs available for these indications are reviewed in The Medical Letter Handbook of Antimicrobial Therapy, 1998.
Med Lett Drugs Ther. 1998 Aug 28;40(1034):85-7 | Show Full IntroductionHide Full Introduction

Trovafloxacin

   
The Medical Letter on Drugs and Therapeutics • March 13, 1998;  (Issue 1022)
Trovafloxacin (Trovan - Pfizer) and its prodrug alatrofoxacin (Trovan IV) are new fluroroquinolones marketed for an unusually wide variety of infections, including oral and intravenous treatment of nosocomial...
Trovafloxacin (Trovan - Pfizer) and its prodrug alatrofoxacin (Trovan IV) are new fluroroquinolones marketed for an unusually wide variety of infections, including oral and intravenous treatment of nosocomial and community-acquired pneumonia, acute ecerbations of chronic bronchitis, acute sinusitis, complicate intra-abdominal and pelvic infections, diabetic foot infection, uncomplicated urinary tract infection, prostatitis, cervicitis and uncomplicated gonorrhea.
Med Lett Drugs Ther. 1998 Mar 13;40(1022):30-1 | Show Full IntroductionHide Full Introduction

Grepafloxacin--A New Fluoroquinolone

   
The Medical Letter on Drugs and Therapeutics • January 30, 1998;  (Issue 1019)
Grepafloxacin (Raxar - Glaxo Wellcome), a once-daily oral fluoroquinolone, is now being marketed for treatment of community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, uncomplicated...
Grepafloxacin (Raxar - Glaxo Wellcome), a once-daily oral fluoroquinolone, is now being marketed for treatment of community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis, uncomplicated gonorrhea, and nongonococcal urethritis and cervicitis.
Med Lett Drugs Ther. 1998 Jan 30;40(1019):17-8 | Show Full IntroductionHide Full Introduction